tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
PremiumRatingsPromising Phase II Results and Strong Financial Position Drive Buy Rating for Rapport Therapeutics
24d ago
Rapport Therapeutics reports Q3 EPS (71c), consensus (73c)
Premium
The Fly
Rapport Therapeutics reports Q3 EPS (71c), consensus (73c)
24d ago
Premium
Company Announcements
Rapport Therapeutics’ New Study on RAP-219: A Potential Game-Changer for Epilepsy Treatment
1M ago
Rapport Therapeutics assigned Buy rating at Goldman Sachs
PremiumThe FlyRapport Therapeutics assigned Buy rating at Goldman Sachs
3M ago
Premium
Company Announcements
Rapport Therapeutics Announces Public Offering Agreement
3M ago
Rapport Therapeutics 9.62M share Secondary priced at $26.00
Premium
The Fly
Rapport Therapeutics 9.62M share Secondary priced at $26.00
3M ago
EchoStar sells spectrum licenses to SpaceX, StubHub to launch IPO: Morning Buzz
PremiumThe FlyEchoStar sells spectrum licenses to SpaceX, StubHub to launch IPO: Morning Buzz
3M ago
Morning Movers: EchoStar jumps following $17B spectrum deal with SpaceX
Premium
The Fly
Morning Movers: EchoStar jumps following $17B spectrum deal with SpaceX
3M ago
Rapport Therapeutics price target raised to $34 from $31 at H.C. Wainwright
Premium
The Fly
Rapport Therapeutics price target raised to $34 from $31 at H.C. Wainwright
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100